Global Neurodegenerative Disease Treatment Report Thumbnail

Global Neurodegenerative Disease Treatment Market by Type (Neurotransmitter Agents, Neuroprotective Agents, Biologics, Others), By Application (Multiple Sclerosis [MS], Alzheimer’s Disease, Parkinson's Disease, Acute Migraine, Autism, Narcolepsy, Amyotrophic Lateral Sclerosis [ALS], Attention Deficit Hyperactivity Disorder [ADHD], Spinal Muscular Atrophy, Huntington's Disease) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

  • Report ID: MC-7426
  • Author: Up Market Research
  • Rating: 4.7
  • Total Reviews: 97
  • No. Of Pages: 250
  • Format:
  • Pub. Date: 2021-04-04
  • Share:

Up Market Research published a new report titled “Neurodegenerative Disease Treatment Market research report which is segmented by Types (Neurotransmitter Agents, Neuroprotective Agents, Biologics, Others), By Applications (Multiple Sclerosis [MS], Alzheimer’s Disease, Parkinson's Disease, Acute Migraine, Autism, Narcolepsy, Amyotrophic Lateral Sclerosis [ALS], Attention Deficit Hyperactivity Disorder [ADHD], Spinal Muscular Atrophy, Huntington's Disease), By Players/Companies Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd.”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.


Report Scope

Report AttributesReport Details
Report TitleNeurodegenerative Disease Treatment Market Research Report
By TypeNeurotransmitter Agents, Neuroprotective Agents, Biologics, Others
By ApplicationMultiple Sclerosis [MS], Alzheimer’s Disease, Parkinson's Disease, Acute Migraine, Autism, Narcolepsy, Amyotrophic Lateral Sclerosis [ALS], Attention Deficit Hyperactivity Disorder [ADHD], Spinal Muscular Atrophy, Huntington's Disease
By CompaniesAllergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Regions CoveredNorth America, Europe, APAC, Latin America, MEA
Base Year2020
Historical Year2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year2028
Number of Pages250
Number of Tables & Figures175
Customization AvailableYes, the report can be customized as per your need.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.


Global Neurodegenerative Disease Treatment Industry Outlook

Global Neurodegenerative Disease Treatment Market Report Segments:

The market is segmented by Type Neurotransmitter Agents, Neuroprotective Agents, Biologics, Others and By Application Multiple Sclerosis [MS], Alzheimer’s Disease, Parkinson's Disease, Acute Migraine, Autism, Narcolepsy, Amyotrophic Lateral Sclerosis [ALS], Attention Deficit Hyperactivity Disorder [ADHD], Spinal Muscular Atrophy, Huntington's Disease.


Some of the companies that are profiled in this report are:

  1. Allergan plc
  2. Bayer AG
  3. F. Hoffmann La-Roche Ltd.
  4. GlaxoSmithKline plc
  5. Johnson & Johnson
  6. Merck KGaA
  7. Novartis AG
  8. Pfizer, Inc.
  9. Sanofi
  10. Teva Pharmaceutical Industries Ltd.

Neurodegenerative Disease Treatment Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.


Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Neurodegenerative Disease Treatment Market

Overview of the regional outlook of the Neurodegenerative Disease Treatment Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.


Neurodegenerative Disease Treatment Market Overview

Highlights of The Neurodegenerative Disease Treatment Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Neurodegenerative Disease Treatment Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

                1. Neurotransmitter Agents

                2. Neuroprotective Agents

                3. Biologics

                4. Others

       7. By Application:

                1. Multiple Sclerosis [MS]

                2. Alzheimer’s Disease

                3. Parkinson's Disease

                4. Acute Migraine

                5. Autism

                6. Narcolepsy

                7. Amyotrophic Lateral Sclerosis [ALS]

                8. Attention Deficit Hyperactivity Disorder [ADHD]

                9. Spinal Muscular Atrophy

                10. Huntington's Disease

  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Neurodegenerative Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.


How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Neurodegenerative Disease Treatment Market Statistics

Reasons to Purchase the Neurodegenerative Disease Treatment Market Report:

  • The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
  • Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
  • Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
  • The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
  • Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neurodegenerative Disease Treatment Market Overview
   4.1 Introduction 
      4.1.1 Market Taxonomy 
      4.1.2 Market Definition 
      4.1.3 Macro-Economic Factors Impacting the Market Growth 
   4.2 Neurodegenerative Disease Treatment Market Dynamics 
      4.2.1 Market Drivers 
      4.2.2 Market Restraints 
      4.2.3 Market Opportunity 
   4.3 Neurodegenerative Disease Treatment Market - Supply Chain Analysis 
      4.3.1 List of Key Suppliers 
      4.3.2 List of Key Distributors 
      4.3.3 List of Key Consumers 
   4.4 Key Forces Shaping the Neurodegenerative Disease Treatment Market 
      4.4.1 Bargaining Power of Suppliers 
      4.4.2 Bargaining Power of Buyers 
      4.4.3 Threat of Substitution 
      4.4.4 Threat of New Entrants 
      4.4.5 Competitive Rivalry 
   4.5 Global Neurodegenerative Disease Treatment Market Size & Forecast, 2018-2028 
      4.5.1 Neurodegenerative Disease Treatment Market Size and Y-o-Y Growth 
      4.5.2 Neurodegenerative Disease Treatment Market Absolute $ Opportunity 


Chapter 5 Global Neurodegenerative Disease Treatment Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Neurodegenerative Disease Treatment Market Size Forecast by Type
      5.2.1 Neurotransmitter Agents
      5.2.2 Neuroprotective Agents
      5.2.3 Biologics
      5.2.4 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Neurodegenerative Disease Treatment Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Neurodegenerative Disease Treatment Market Size Forecast by Applications
      6.2.1 Multiple Sclerosis [MS]
      6.2.2 Alzheimer’s Disease
      6.2.3 Parkinson's Disease
      6.2.4 Acute Migraine
      6.2.5 Autism
      6.2.6 Narcolepsy
      6.2.7 Amyotrophic Lateral Sclerosis [ALS]
      6.2.8 Attention Deficit Hyperactivity Disorder [ADHD]
      6.2.9 Spinal Muscular Atrophy
      6.2.10 Huntington's Disease
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Neurodegenerative Disease Treatment Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Neurodegenerative Disease Treatment Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Neurodegenerative Disease Treatment Analysis and Forecast
   9.1 Introduction
   9.2 North America Neurodegenerative Disease Treatment Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Neurodegenerative Disease Treatment Market Size Forecast by Type
      9.6.1 Neurotransmitter Agents
      9.6.2 Neuroprotective Agents
      9.6.3 Biologics
      9.6.4 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Neurodegenerative Disease Treatment Market Size Forecast by Applications
      9.10.1 Multiple Sclerosis [MS]
      9.10.2 Alzheimer’s Disease
      9.10.3 Parkinson's Disease
      9.10.4 Acute Migraine
      9.10.5 Autism
      9.10.6 Narcolepsy
      9.10.7 Amyotrophic Lateral Sclerosis [ALS]
      9.10.8 Attention Deficit Hyperactivity Disorder [ADHD]
      9.10.9 Spinal Muscular Atrophy
      9.10.10 Huntington's Disease
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Neurodegenerative Disease Treatment Analysis and Forecast
   10.1 Introduction
   10.2 Europe Neurodegenerative Disease Treatment Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Neurodegenerative Disease Treatment Market Size Forecast by Type
      10.6.1 Neurotransmitter Agents
      10.6.2 Neuroprotective Agents
      10.6.3 Biologics
      10.6.4 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Neurodegenerative Disease Treatment Market Size Forecast by Applications
      10.10.1 Multiple Sclerosis [MS]
      10.10.2 Alzheimer’s Disease
      10.10.3 Parkinson's Disease
      10.10.4 Acute Migraine
      10.10.5 Autism
      10.10.6 Narcolepsy
      10.10.7 Amyotrophic Lateral Sclerosis [ALS]
      10.10.8 Attention Deficit Hyperactivity Disorder [ADHD]
      10.10.9 Spinal Muscular Atrophy
      10.10.10 Huntington's Disease
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Neurodegenerative Disease Treatment Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Neurodegenerative Disease Treatment Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Neurodegenerative Disease Treatment Market Size Forecast by Type
      11.6.1 Neurotransmitter Agents
      11.6.2 Neuroprotective Agents
      11.6.3 Biologics
      11.6.4 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Neurodegenerative Disease Treatment Market Size Forecast by Applications
      11.10.1 Multiple Sclerosis [MS]
      11.10.2 Alzheimer’s Disease
      11.10.3 Parkinson's Disease
      11.10.4 Acute Migraine
      11.10.5 Autism
      11.10.6 Narcolepsy
      11.10.7 Amyotrophic Lateral Sclerosis [ALS]
      11.10.8 Attention Deficit Hyperactivity Disorder [ADHD]
      11.10.9 Spinal Muscular Atrophy
      11.10.10 Huntington's Disease
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Neurodegenerative Disease Treatment Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Neurodegenerative Disease Treatment Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Neurodegenerative Disease Treatment Market Size Forecast by Type
      12.6.1 Neurotransmitter Agents
      12.6.2 Neuroprotective Agents
      12.6.3 Biologics
      12.6.4 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Neurodegenerative Disease Treatment Market Size Forecast by Applications
      12.10.1 Multiple Sclerosis [MS]
      12.10.2 Alzheimer’s Disease
      12.10.3 Parkinson's Disease
      12.10.4 Acute Migraine
      12.10.5 Autism
      12.10.6 Narcolepsy
      12.10.7 Amyotrophic Lateral Sclerosis [ALS]
      12.10.8 Attention Deficit Hyperactivity Disorder [ADHD]
      12.10.9 Spinal Muscular Atrophy
      12.10.10 Huntington's Disease
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Neurodegenerative Disease Treatment Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Neurodegenerative Disease Treatment Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Neurodegenerative Disease Treatment Market Size Forecast by Type
      13.6.1 Neurotransmitter Agents
      13.6.2 Neuroprotective Agents
      13.6.3 Biologics
      13.6.4 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Neurodegenerative Disease Treatment Market Size Forecast by Applications
      13.10.1 Multiple Sclerosis [MS]
      13.10.2 Alzheimer’s Disease
      13.10.3 Parkinson's Disease
      13.10.4 Acute Migraine
      13.10.5 Autism
      13.10.6 Narcolepsy
      13.10.7 Amyotrophic Lateral Sclerosis [ALS]
      13.10.8 Attention Deficit Hyperactivity Disorder [ADHD]
      13.10.9 Spinal Muscular Atrophy
      13.10.10 Huntington's Disease
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Neurodegenerative Disease Treatment Market: Competitive Dashboard
   14.2 Global Neurodegenerative Disease Treatment Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Allergan plc
      14.3.2 Bayer AG
      14.3.3 F. Hoffmann La-Roche Ltd.
      14.3.4 GlaxoSmithKline plc
      14.3.5 Johnson & Johnson
      14.3.6 Merck KGaA
      14.3.7 Novartis AG
      14.3.8 Pfizer, Inc.
      14.3.9 Sanofi
      14.3.10 Teva Pharmaceutical Industries Ltd.
Segments Covered in the Report
The global Neurodegenerative Disease Treatment market has been segmented based on

By Types
  • Neurotransmitter Agents
  • Neuroprotective Agents
  • Biologics
  • Others
By Applications
  • Multiple Sclerosis [MS]
  • Alzheimer’s Disease
  • Parkinson's Disease
  • Acute Migraine
  • Autism
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis [ALS]
  • Attention Deficit Hyperactivity Disorder [ADHD]
  • Spinal Muscular Atrophy
  • Huntington's Disease
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Allergan plc
  • Bayer AG
  • F. Hoffmann La-Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Buy Report